LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

Search

Novocure Ltd

Atidarymo kaina

SektoriusSveikatos priežiūra

17.53 -1.41

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

17.43

Max

18.27

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-47M

-71M

Pardavimai

-295K

174M

Pelnas, tenkantis vienai akcijai

-0.62

Pelno marža

-40.871

Darbuotojai

1,605

EBITDA

-29M

-63M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+46.23% upside

Dividendai

By Acuity

Kitas uždarbis

2026-07-23

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

506M

2B

Ankstesnė atidarymo kaina

18.94

Ankstesnė uždarymo kaina

17.53

Naujienos nuotaikos

By Acuity

50%

50%

146 / 342 reitingas Healthcare

Novocure Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Apie bendrovę Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
help-icon Live chat